Display options
Cite
Tóth N, Soós A, Váradi A, et al. Effect of ivabradine in heart failure: a meta-analysis of heart failure patients with reduced versus preserved ejection fraction. Can J Physiol Pharmacol. 2021;99(11):1159-1174doi: 10.1139/cjpp-2020-0700.
Tóth, N., Soós, A., Váradi, A., Hegyi, P., Tinusz, B., Vágvölgyi, A., Orosz, A., Solymár, M., Polyák, A., Varró, A., Farkas, A. S., & Nagy, N. (2021). Effect of ivabradine in heart failure: a meta-analysis of heart failure patients with reduced versus preserved ejection fraction. Canadian journal of physiology and pharmacology, 99(11), 1159-1174. https://doi.org/10.1139/cjpp-2020-0700
Tóth, Noémi, et al. "Effect of ivabradine in heart failure: a meta-analysis of heart failure patients with reduced versus preserved ejection fraction." Canadian journal of physiology and pharmacology vol. 99,11 (2021): 1159-1174. doi: https://doi.org/10.1139/cjpp-2020-0700
Tóth N, Soós A, Váradi A, Hegyi P, Tinusz B, Vágvölgyi A, Orosz A, Solymár M, Polyák A, Varró A, Farkas AS, Nagy N. Effect of ivabradine in heart failure: a meta-analysis of heart failure patients with reduced versus preserved ejection fraction. Can J Physiol Pharmacol. 2021 Nov;99(11):1159-1174. doi: 10.1139/cjpp-2020-0700. Epub 2021 Oct 12. PMID: 34636643.
Copy Download .nbib Format: NLM
Share it on

Can J Physiol Pharmacol. 2021 Nov;99(11):1159-1174. doi: 10.1139/cjpp-2020-0700. Epub 2021 Oct 12.

Effect of ivabradine in heart failure: a meta-analysis of heart failure patients with reduced versus preserved ejection fraction.

Canadian journal of physiology and pharmacology

Noémi Tóth, Alexandra Soós, Alex Váradi, Péter Hegyi, Benedek Tinusz, Anna Vágvölgyi, Andrea Orosz, Margit Solymár, Alexandra Polyák, András Varró, Attila S Farkas, Norbert Nagy

Affiliations

  1. Department of Pharmacology and Pharmacotherapy, Albert Szent-Györgyi Medical School University of Szeged, Dóm Square 12, Szeged 6720, Hungary.
  2. Institute for Translational Medicine, Medical School, University of Pécs, 12 Szigeti Street, Pécs 7624, Hungary.
  3. First Department of Medicine, Medical School, University of Pécs, Ifjúság Street 13, Pécs 7624, Hungary.
  4. Department of Internal Medicine, Albert Szent-Györgyi Medical School University of Szeged, Kálvária sgt. 57, Szeged 6720, Hungary.
  5. ELKH-SZTE Research Group of Cardiovascular Pharmacology, Szeged, Hungary.

PMID: 34636643 DOI: 10.1139/cjpp-2020-0700

Abstract

In clinical trials of heart failure reduced ejection fraction (HFrEF), ivabradine seemed to be an effective heart rate lowering agent associated with lower risk of cardiovascular death. In contrast, ivabradine failed to improve cardiovascular outcomes in heart failure preserved ejection fraction (HFpEF) despite the significant effect on heart rate. This meta-analysis is the first to compare the effects of ivabradine on heart rate and mortality parameters in HFpEF versus HFrEF. We screened three databases: PubMed, Embase, and Cochrane Library. The outcomes of these studies were mortality, reduction in heart rate, and left ventricular function improvement. We compared the efficacy of ivabradine treatment in HFpEF versus HFrEF. Heart rate analysis of pooled data showed decrease in both HFrEF (-17.646 beats/min) and HFpEF (-11.434 beats/min), and a tendency to have stronger bradycardic effect in HFrEF (

Keywords: fonction ventriculaire gauche; fréquence cardiaque; heart failure; heart failure preserved ejection fraction; heart failure reduced ejection fraction; heart rate; insuffisance cardiaque; insuffisance cardiaque à fraction d’éjection préservée; insuffisance cardiaque à fraction d’éjection réduite; ivabradine; left ventricular function

Publication Types